MIRA’s Ketamir-2 Shows 60% More Effectiveness Than Gabapentin In Reducing Chemotherapy-induced Pain

MIRA Pharmaceuticals, Inc., a prime preclinical-stage company, has released promising preclinical data on its new oral ketamine analog, Ketamir-2. This novel compound demonstrated 60% higher effectiveness than gabapentin. Gabapentin is the FDA-approved standard for neuropathic pain in reducing chemotherapy-induced pain. Ketamir-2 has shown consistent success across different pain models, suggesting it could become a transformative option for pain management.

Researchers stimulated neuropathic pain in mice using a paclitaxel (PTX) model. The PTX chemotherapy model mimics nerve damage, wherein symptoms range from pain to tingling or numbness. In this study, on day 9, nearly normalized pain sensitivity was noted in mice subjected to the optimal dose of 300 mg/kg Ketamir-2, surpassing gabapentin by 60%, resulting in moderate pain relief.

MIRA Pharmaceuticals will introduce these discoveries at the Pain Therapeutics Summit in Boston on October 28-29, 2024, featuring Ketamir-2's actual capacity and encouraging discourse with specialists in the field. This event features MIRA's dedication to imparting its information to mainstream researchers and facilitating the growth of Ketamir-2 as a novel approach to pain relief.